By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SeraCare Life Sciences has signed a definitive agreement to be acquired by private equity firm Linden Capital Partners for $4 per share, or around $82 million.

The purchase price represents a 25 percent premium to the 30-day volume-weighted average stock price of SeraCare. The Milford, Mass.-based firm, which makes life sciences tools including molecular biomarkers and controls, would become a private company, wholly owned by Linden.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.